Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Receivables (2016 - 2025)

IGC Pharma (IGC) has disclosed Receivables for 15 consecutive years, with $711000.0 as the latest value for Q3 2025.

  • Quarterly Receivables fell 2.47% to $711000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $711000.0 through Sep 2025, down 2.47% year-over-year, with the annual reading at $714000.0 for FY2025, 1.52% down from the prior year.
  • Receivables for Q3 2025 was $711000.0 at IGC Pharma, down from $767000.0 in the prior quarter.
  • The five-year high for Receivables was $1.2 million in Q2 2023, with the low at $493000.0 in Q1 2022.
  • Average Receivables over 5 years is $764947.4, with a median of $725000.0 recorded in 2024.
  • The sharpest move saw Receivables soared 134.73% in 2023, then plummeted 39.29% in 2024.
  • Over 5 years, Receivables stood at $546000.0 in 2021, then surged by 83.52% to $1.0 million in 2022, then grew by 3.59% to $1.0 million in 2023, then fell by 29.87% to $728000.0 in 2024, then dropped by 2.34% to $711000.0 in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $711000.0, $767000.0, and $714000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.